🔔 Pharmaceutical Sales Growth in 2025 – Top 3 Drivers of the Year! https://lnkd.in/dP9gvVrn 🔜 In 2025, #pharmaceutical #sales are set to return to their normal growth patterns, excluding the COVID-affected years. Analysts predict a remarkable $72bn increase over 2024, marking the largest annual growth in a decade outside of the 2021 spike. ➡️ This #newsletter, authored by Avisek Ghose, is focusing on the top three growth areas — solid #tumors, metabolic disorders, and #diabetes #treatments, which are expected to drive significant #market expansion, contributing a combined $34.5bn to the overall $54bn growth from the top 10 #therapeutic areas. Let’s have a look at the statistics of the prediction! ⬆️ Read here: https://lnkd.in/dP9gvVrn 🌐 Subscribe to our newsletter for regular updates: https://lnkd.in/dhn-k5KZ #pharmamarket #marketanalysis #pharmasales #markettrend
Inferre Consulting GmbH
Marketingdienstleistungen
Basel, Switzerland 131 Follower:innen
From Innovation to Impact: Strategic Solutions for Healthcare Market Leadership
Info
At Inferre Consulting, our goal is to provide evidence based strategic solutions for healthcare market leadership. 🔝 From Innovation to Impact: Our consulting firm is dedicated to the Biopharma, Medical Device, and Life Science industries. Our mission is to empower your business with comprehensive, data-driven insights and strategic solutions that drive innovation and success. Our Market Access offerings; ➡️ Market Research: Expertise in Epidemiology, PICO Analysis, Literature Review, Competitor Intelligence, and KOL Mapping. ➡️ Reimbursement Policy & Tariff Assessment: Optimizing market access through comprehensive reimbursement strategies. ➡️ HTA Case Study: Delivering thorough Health Technology Assessments to enhance product value. ➡️ Expert/KOL Interviews: Connecting with key opinion leaders for valuable insights. ➡️ Business Development: Identifying the right markets and clients to drive growth. ➡️ Systematic Literature Review: Providing meticulous reviews to support research and development. ➡️ Market Intelligence & Reports: Offering detailed market analysis to inform strategic decisions. ➡️ HEOR, RWD, RWE: Utilizing Health Economics and Outcomes Research, Real-World Data, and Real-World Evidence to demonstrate product value. ➡️ Market Access & Pricing Tools: Developing strategies for successful market entry and competitive pricing. ➡️ End-to-End Support from concept to patient care. At Inferre Consulting we are committed to be your trusted partner in navigating the complexities of the Biopharma, Medical Device, and Life Science industries. Your market access projects are in experienced hands. Let’s join to achieve excellence and make a meaningful impact on patient lives. 🔔 Inferre Consulting GmbH is registered at the Registries of Commerce of Switzerland
- Website
-
https://www.inferreconsult.com/
Externer Link zu Inferre Consulting GmbH
- Branche
- Marketingdienstleistungen
- Größe
- 2–10 Beschäftigte
- Hauptsitz
- Basel, Switzerland
- Art
- Privatunternehmen
- Gegründet
- 2023
- Spezialgebiete
- Market Access, Market Research, Business Development, Systematic Literature Review, KOL Mapping, Reimbursement Policy and Tariff Assessment, HTA Case Study, HEOR, Expert / KOL Interview, Competitor Intelligence, Market Intelligence Reports, Medical Device, Biopharma und Life Science
Orte
-
Primär
Basel, Switzerland 4053, CH
Updates
-
➡️ Recent News on Health Economics and Outcomes Research (#HEOR) ☑️ GPT-3’s Diagnostic Accuracy A study in The Lancet Digital Health shows GPT-3 correctly diagnosed cases in its top 3 predictions 88% of the time, outperforming lay individuals (54%) and closely trailing physicians (96%). However, it deprioritized truly emergent cases in 7 instances. ☑️ Healthcare Systems & HEOR As highlighted in Value & Outcomes Spotlight, #healthcare systems are striving to balance advanced treatments with affordability and accessibility, aiming to provide optimal care at reasonable costs. ☑️ Medicaid & Data Science Health Affairs Forefront critiques value-based care models in Medicaid as “value veneers” due to data quality issues and poor integration of #clinical and social risk factors, limiting their effectiveness. ☑️ National Health Expenditure Projections Health Affairs reports a 7.5% growth in national health expenditures in 2023 post-COVID-19 emergency. From 2027-2032, healthcare spending is expected to outpace economic growth due to price inflation and increased service use. ☑️ ISPOR’s Strategic Plan 2030 ISPOR’s new plan envisions a future where healthcare is accessible, effective, efficient, and affordable for all. ☑️ Health Literacy & Equity Health Affairs emphasizes the need for strategies to improve health literacy and digital health literacy to advance health equity. ☑️ Medicare Savings Program Policy experts suggest aligning MSP eligibility with the Medicare Part D Low-Income Subsidy program to increase enrollment and improve care for dual-eligible individuals. ☑️ Remote Symptom Monitoring in Oncology A study in The Lancet Regional Health #Europe shows that remote #patient monitoring in 33 #cancer centers led to significant symptom improvement in 94.6% of cases within 2 weeks. ☑️ NICE & Drug Pricing NICE and #NHS England express disappointment over high pricing for Enhertu, preventing its recommendation for advanced HER2-low breast cancer. ☑️ Cost-Saving Clot-Busting Drug NICE recommends Tenecteplase, a cost-effective alternative for treating acute ischemic stroke, potentially saving the NHS millions. ☑️ Pandemic Preparedness CEPI and WHO call for broader research on pathogen families to prepare for future pandemics, using “prototype pathogens” as guides. ☑️ mRNA Vaccine Development Sinergium Biotech, supported by WHO and the Medicines Patent Pool, is advancing mRNA vaccines for avian influenza in low- and middle-income countries. ➕ Source: ISPOR—The Professional Society for Health Economics and Outcomes Research news desk. 📌 Author: Avisek Ghose #healthcare #AI #medicaid #healthequity #pandemicpreparedness #mRNA #ISPOR #NICE #GPT3 #digitalhealth
-
-
Top-5 Pharma News and Market Trend in 2024 - #newsletter from Avisek Ghose
Market Access Specialist | EMEA | Medical Device & Pharma | Translating Market Insights into Actionable Business Strategies
"Top-5 Pharma News and Market Trend in 2024" - my latest #newsletter is looking beyond the uncertainties of the previous year, the #pharma outlook for 2024, and top-5 Pharma news across the globe. Enjoy insightful reading, complete with essential market citations. #pharmaindustry #pharmamarkettrend #pharmanews #marketresearch
Top-5 Pharma News and Market Trend in 2024
Avisek Ghose auf LinkedIn
-
The #pharmaceutical industry’s outlook for 2024 by Robert F. Siegmund, PhD MBA is shaped by several key themes like Health System Reforms, Demographic Shifts, Changing #Patient Experiences and Expectations. #biopharma #insights #analytics
Business Development Partner in BioPharma | Insights & Analytics | Real-World Data | Real-World Evidence | AI & Data Science Expert | PhD Genetics (University of Vienna) | MBA (London Business School)
Evaluate Ltd's 𝗪𝗼𝗿𝗹𝗱 𝗣𝗿𝗲𝘃𝗶𝗲𝘄 𝟮𝟬𝟮𝟰 🔹𝟐𝟎𝟐𝟒 𝐌𝐚𝐫𝐤𝐞𝐭 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰: As we move beyond last year's uncertainties, the 2024 outlook anticipates a more predictable environment. With a focus on obesity and other significant diseases, the industry is navigating through new modalities and adapting to permanent changes like the Inflation Reduction Act. This year is pivotal as companies align their strategies to these evolving realities. 🔹 𝟐𝟎𝟑𝟎 𝐒𝐚𝐥𝐞𝐬 𝐚𝐧𝐝 𝐆𝐫𝐨𝐰𝐭𝐡 𝐏𝐫𝐨𝐣𝐞𝐜𝐭𝐢𝐨𝐧𝐬: The report predicts that total prescription drug sales will reach $1.7 trillion by 2030, with a significant contribution from obesity drugs: 𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐲: Expected to remain the leader with sales surpassing $370 billion. 𝐂𝐍𝐒 𝐃𝐢𝐬𝐨𝐫𝐝𝐞𝐫𝐬: Projected at $166 billion. 𝐎𝐛𝐞𝐬𝐢𝐭𝐲 & 𝐃𝐢𝐚𝐛𝐞𝐭𝐞𝐬: A substantial focus area, with $121 billion in sales anticipated. The 𝟕.𝟕% 𝐂𝐀𝐆𝐑 projection appears optimistic, suggesting a reevaluation towards a more conservative growth estimate might be prudent given the broader industry challenges. 🔹 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐢𝐜𝐚𝐥 𝐀𝐝𝐯𝐚𝐧𝐜𝐞𝐬: The sector is poised for breakthroughs with advancements in antibody-drug conjugates (ADCs), multi-specific antibodies, RNA-based therapies, and gene/cell therapies. These are expected to drive substantial market changes and offer new therapeutic options. 🔹 𝐌𝐚𝐫𝐤𝐞𝐭 𝐏𝐫𝐞𝐬𝐬𝐮𝐫𝐞𝐬 𝐚𝐧𝐝 𝐂𝐡𝐚𝐧𝐠𝐢𝐧𝐠 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐌𝐨𝐝𝐞𝐥𝐬: The industry faces downward pricing pressures across developed markets and higher reimbursement hurdles for new drugs, signaling a shift from the blockbuster model towards more targeted therapies. This strategic pivot is making it challenging to replace old blockbusters with new treatments that offer marginal improvements. 🔹𝐂𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐞𝐬 𝐀𝐡𝐞𝐚𝐝: 𝐏𝐚𝐭𝐞𝐧𝐭 𝐄𝐱𝐩𝐢𝐫𝐢𝐞𝐬 𝐚𝐧𝐝 𝐑𝐞𝐠𝐮𝐥𝐚𝐭𝐨𝐫𝐲 𝐂𝐡𝐚𝐧𝐠𝐞𝐬: Patent expiries continue to be a significant concern, with an estimated 𝟔.𝟔% 𝐨𝐟 𝐭𝐨𝐭𝐚𝐥 𝐬𝐚𝐥𝐞𝐬 𝐚𝐭 𝐫𝐢𝐬𝐤 𝐟𝐫𝐨𝐦 𝐋𝐎𝐄 at the midpoint of the forecast period (2027) This, along with the ongoing adjustments to the Inflation Reduction Act, underscores the need for strategic adaptations within the pharmaceutical industry. This enhanced outlook for 2024 and beyond integrates professional insights with broad industry forecasts, providing a comprehensive view of the evolving pharmaceutical landscape. Source: Evaluate Ltd., Life Code GmbH Analysis, 9.7.24 #biopharma #insights #analytics
-
Inferre Consulting GmbH hat dies direkt geteilt
Market Access Specialist | EMEA | Medical Device & Pharma | Translating Market Insights into Actionable Business Strategies
🔜 (Are you) Entering Switzerland with Medicinal Products? 🔔 Different rules for different #pharma #products in 🇨🇭 🌐 https://lnkd.in/dEV7rzUM ☑️ Remember to follow the guidelines from Swissmedic to ensure a smooth entry with your medicinal products! #pharmaregulation #swisspharma #swissmedic
Entering Switzerland with medicinal products
swissmedic.ch
-
Hello LinkedIn community! 👋 👉 I am currently looking for a skilled #webdesigner to enhance the graphical representation and content of my #website (https://lnkd.in/gA7R5EY6). This is a #WordPress based #website and will be re-launched with better features for visually appealing. Overview: ☑️ Improving the website’s aesthetics, content and usability. ☑️ Including plugins (#SEO etc.) to improve visitor experience and traffic. ☑️ Creating stunning visuals, infographics, and data visualizations. 🤝 Could be a good learning experience for upcoming web designers. ➡️ Please send a direct #message to Avisek Ghose if you are ready to take this small #project. ➡️ Feel free to share this post or tag talented designers you know. #webdesign #UX #webdesigners
Home
http://healthcare-market-insight.com
-
Insightful #newsletter from Avisek Ghose
Market Access Specialist | EMEA | Medical Device & Pharma | Translating Market Insights into Actionable Business Strategies
🗣 "In the methodical progression of health economics, each analytical maneuver is pivotal in the systematic construction of a healthcare framework that harmonizes the principles of efficiency and equity." ➡️ My latest #newsletter “The Impact of Health Economics on Healthcare Outcomes: An Expert's Perspective” focuses on the importance of understanding the #economic implications of #medical interventions in the ever-evolving landscape of #healthcare. 🔔 Uncover the complexities and nuances of health economics that drive decision-making in healthcare systems around the globe. ➡️ Disclaimer This newsletter is part of an Expert/KOL #interview, conducted recently by Avisek Ghose, shedding light on how #HEOR studies can reveal disparities in healthcare, guiding efforts to improve access and equity. With due respect to our Non-Disclosure Agreement, only publishable information have been summarized here. Expert's identity is also classified, therefore named as Dr. Daniel. #expertinterview #marketaccess #economicevaluation #avisekghose #patientaccess
The Impact of Health Economics on Healthcare Outcomes: An Expert's Perspective
Avisek Ghose auf LinkedIn
-
Inferre Consulting GmbH hat dies direkt geteilt
Market Access Specialist | EMEA | Medical Device & Pharma | Translating Market Insights into Actionable Business Strategies
👉 Free up your time for other responsibilities; 🔜 As an experienced associate to manage #Pharma and #MedTech market research and market access projects, I am extending my service as “job-shadowing” and available for the next couple of months, with a maximum commitment of 0.35 FTE. ➡️ My top-5 relevant contributions; ✔️ Secondary Market Research: document/literature review, epidemiology, #HTA, #reimbursement policies, etc. ✔️ Analyzing MedTech and Pharma market for dedicated product portfolio and geography ✔️ Regulatory challenges in European and APAC markets ✔️ #KOL Mapping and Expert #interviews ✔️ preparing Business case studies 🔈 Let’s discuss and explore potential #collaboration and mutual benefits. 🔔 For fair business policy, NDA will be signed. #marketresearch #marketaccess #projectmanagment #jobshadowing #job #hire #hireanexpert #consultation #recruitment
-
-
Recent #publication in #healtheconomics!
Market Access Specialist | EMEA | Medical Device & Pharma | Translating Market Insights into Actionable Business Strategies
🔝 Pricing, Procurement and Reimbursement Policies for Incentivizing Market Entry of Novel Antibiotics and Diagnostics: Learnings from 10 Countries Globally ➡️ Recent publication from Applied Health Economics and Health Policy © Sabine Vogler et al. Appl. Health Econ. Health Policy (2024). DOI: 10.1007/s40258-024-00888-y (published on 05 June 2024) ☑️ To address antimicrobial resistance (#AMR), promoting the market entry of new #antibiotics and improving antibiotic prescribing through better #diagnostics are essential strategies – this article examines pull incentives in #pricing, procurement, and #reimbursement policies for novel antibiotics and diagnostics in 10 of the G-20 countries, and considers if similar incentives for non-AMR health products could be applied to AMR products. ☑️ Pull incentives for pricing #policies include free pricing, higher launch prices, price increases over time, managed-entry agreements, and reduced mandatory discounts. Procurement incentives involve value-based procurement, pooled procurement, and subscription-based pricing, while #reimbursement incentives encompass lower evidence requirements, faster reimbursement processes, separate budgets with additional funding, and tailored prescribing conditions. ☑️ Although some pull incentives have recently been tested or implemented for antibiotics, they have primarily been used for launching non-AMR #health products like orphan #medicines. Due to similar product characteristics, these incentives could potentially be adapted for antibiotics, but impact assessments are necessary, and the balance between improving access and ensuring #financial sustainability for #payers must be considered. 🔔 For more detail please refer to the original article. DOI: 10.1007/s40258-024-00888-y #orphanmedicine #raredisease #pharmapricing #antimicrobialresistance #healtheconomics
-
-
Inferre Consulting GmbH hat dies direkt geteilt
Market Access Specialist | EMEA | Medical Device & Pharma | Translating Market Insights into Actionable Business Strategies
🔝 The Importance of Responsible and Transparent Communications in Pharma Marketing ➡️ Citing the article by Marcella Milliet Sciorra, published on Pharmaceutical Executive on January 22nd, 2024, let’s evaluate how effective #corporate #communication plays a crucial role in the context of #pharma market access. ☑️ Building Trust and Credibility: Clear communication fosters trust between pharmaceutical companies, healthcare professionals (#HCPs), and other stakeholders. When companies transparently share information about their products, #pricing, and #clinical evidence, it enhances credibility and strengthens relationships. ☑️ Navigating Market Access Challenges: Market access involves demonstrating clinical and #economic evidence, negotiating with payers, and ensuring timely product availability for patients. Effective communication helps address access challenges, ensuring that patients receive the therapies they need. ☑️ Strategic Choices and Alignment: Companies must formulate clear access objectives aligned with overall commercial goals. Communication ensures cross-functional alignment, clarifies roles, and optimizes processes across functions and affiliates. ☑️ Early Engagement: Communication should begin early in drug development, incorporating market access perspectives. Engaging a wider set of industry stakeholders and fostering cross-functional collaboration are essential for successful launches. ➡️ Key message: Pharma #marketing strategies that are both socially and ethically responsible can build long term success for the life sciences industry. #marketaccess #marketingstrategies #corporatecommunication #pharmamarketing
-